Cambrex Corp. (NYSE:CBM) fell 1.5% during mid-day trading on Friday . The company traded as low as $57.68 and last traded at $57.97, with a volume of 122,317 shares trading hands. The stock had previously closed at $58.85.

Separately, Zacks Investment Research raised shares of Cambrex Corp. from a “hold” rating to a “strong-buy” rating and set a $56.00 price target on the stock in a research note on Wednesday, May 4th.

The stock’s 50 day moving average price is $52.41 and its 200-day moving average price is $44.91. The company has a market cap of $1.84 billion and a price-to-earnings ratio of 29.50.

Cambrex Corp. (NYSE:CBM) last posted its earnings results on Friday, April 29th. The company reported $0.50 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.34 by $0.16. The business had revenue of $94.74 million for the quarter, compared to analysts’ expectations of $83.61 million. The business’s revenue was up 22.2% compared to the same quarter last year. During the same quarter last year, the business posted $0.29 earnings per share. On average, analysts anticipate that Cambrex Corp. will post $2.56 earnings per share for the current fiscal year.

In other news, CEO Steven M. Klosk sold 16,430 shares of Cambrex Corp. stock in a transaction dated Thursday, May 5th. The shares were sold at an average price of $49.13, for a total transaction of $807,205.90. Following the completion of the sale, the chief executive officer now directly owns 136,828 shares in the company, valued at $6,722,359.64. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director William B. Korb sold 3,420 shares of Cambrex Corp. stock in a transaction dated Monday, July 11th. The stock was sold at an average price of $55.00, for a total transaction of $188,100.00. Following the sale, the director now owns 23,982 shares of the company’s stock, valued at $1,319,010. The disclosure for this sale can be found here.

Several large investors have recently modified their holdings of CBM. Pear Tree Advisors Inc. purchased a new stake in shares of Cambrex Corp. during the fourth quarter worth approximately $1,008,000. GSA Capital Partners LLP increased its stake in shares of Cambrex Corp. by 33.2% in the fourth quarter. GSA Capital Partners LLP now owns 26,475 shares of the company’s stock worth $1,247,000 after buying an additional 6,592 shares during the period. Stevens Capital Management LP increased its stake in shares of Cambrex Corp. by 79.0% in the fourth quarter. Stevens Capital Management LP now owns 28,241 shares of the company’s stock worth $1,330,000 after buying an additional 12,460 shares during the period. Bank of Montreal Can increased its stake in shares of Cambrex Corp. by 31.1% in the fourth quarter. Bank of Montreal Can now owns 31,339 shares of the company’s stock worth $1,476,000 after buying an additional 7,431 shares during the period. Finally, Turner Investments L.P. purchased a new stake in shares of Cambrex Corp. during the fourth quarter worth approximately $2,119,000.

Cambrex Corporation (Cambrex) is a life sciences company. The Company provides products and services for the development and commercialization of new and generic therapeutics. The Company supplies its products and services across the world to generic pharmaceutical companies. Cambrex operates through three segments, which are manufacturing facilities.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.